Moderna's Price Plummets by 7% as Valuation Raises Questions

Moderna's stock price plummeted by 7% on Wednesday, following a 14% surge on Tuesday after Wolfe Research upgraded the company to Peer Perform from Underperform. The upgrade was based on unadjusted peak sales of $9.2 billion for Moderna's personalized cancer vaccine, intismeran, which it is developing with Merck. However, this recent price drop raises questions about what a market capitalization of nearly $59 billion actually values in terms of income statement results.

Moderna's revenue was only $145 million in Q2 2026, up 2.1% year-over-year, and the company posted a net loss of $782 million. The bear case is that this valuation embeds a drug not yet approved on a revenue base of just $145 million per quarter.

The biotech cluster, as measured by the iShares Biotechnology ETF, was barely affected by Moderna's drop, falling only 0.6%. BioNTech SE, which has been moving in tandem with Moderna, slipped by 2% to $111.60. The company's management guides to up to 10% revenue growth in 2026 and year-end cash and investments of $4.7 billion to $5.2 billion.

Investors are advised to keep position sizing modest and define their risk budget before adding on either dips or breakouts, as recent moves have been remarkably compressed on a shorter frame.